Ramón García‐Sánz

Active 1948–2025

Also published as
Ramon Garcia-Sanz
153
Papers
22,032
Citations
80
h-index
148
i10-index

Citations

Citations per year for Ramón García‐Sánz1993: 2 citations1995: 2 citations1996: 4 citations1997: 3 citations1998: 12 citations1999: 20 citations2000: 28 citations2001: 24 citations2002: 21 citations2003: 33 citations2004: 53 citations2005: 74 citations2006: 74 citations2007: 83 citations2008: 112 citations2009: 107 citations2010: 136 citations2011: 125 citations2012: 122 citations2013: 131 citations2014: 160 citations2015: 163 citations2016: 139 citations2017: 150 citations2018: 151 citations2019: 547 citations2020: 640 citations2021: 741 citations2022: 609 citations2023: 383 citations2024: 692 citations2025: 266 citations2026: 11 citations1994: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,779 citing papers, 20.1% of this breakdownItaly: 699 citing papers, 7.9% of this breakdownSpain: 680 citing papers, 7.7% of this breakdownGermany: 600 citing papers, 6.8% of this breakdownFrance: 545 citing papers, 6.1% of this breakdownUnited Kingdom: 540 citing papers, 6.1% of this breakdownNetherlands: 413 citing papers, 4.7% of this breakdownChina: 400 citing papers, 4.5% of this breakdownGreece: 258 citing papers, 2.9% of this breakdownAustralia: 245 citing papers, 2.8% of this breakdownCanada: 217 citing papers, 2.4% of this breakdownCzechia: 197 citing papers, 2.2% of this breakdown
0%20.1%Other 25.8%

Fields

  • Medicine84.1%
  • Biochemistry, Genetics and Molecular Biology9.6%
  • Immunology and Microbiology4.4%
  • Engineering0.5%
  • Pharmacology, Toxicology and Pharmaceutics0.3%
  • Neuroscience0.2%
  • Other0.9%

Topics

  • Multiple Myeloma Research and Treatments13.4%
  • Lymphoma Diagnosis and Treatment7.3%
  • Chronic Lymphocytic Leukemia Research6.6%
  • Protein Degradation and Inhibitors5.7%
  • Peptidase Inhibition and Analysis3%
  • CAR-T cell therapy research2.7%
  • Other61.3%

Coauthors

All papers

Open in search
  1. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brian G.M. Durie, Jacques J. M. van Dongen, A Orfao - Leukemia 2017 cited by 657

  2. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Aileen Cohen, Jane Huang, Meletios Α. Dimopoulos - Blood 2020 cited by 448

  3. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Baldeep Wirk, Matthew T. Drake, Michèle Cavo, Juan José Lahuerta, Suzanne Lentzsch - The Lancet Oncology 2019 cited by 496

  4. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936

    Authors: , , , , , , , , , , , , , , , , , , , , , - Leukemia 2003 cited by 3,041

  5. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells

    Authors: , , , , , , , , , , , , , , - Blood 2007 cited by 575

  6. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alberto Órfão, María‐Victoria Mateos, Joan Bladé, Jesús F. San Miguel, Juan José Lahuerta, on behalf of the GEM (Grupo Español de Mieloma)/PETHEMA (Programa Para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group - Journal of Clinical Oncology 2019 cited by 276

  7. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

    Authors: , , , , , , , , , , , , , , , , , , - Blood 2020 cited by 151

  8. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

    Authors: , , , , , , , , , , , , - The Lancet Oncology 2018 cited by 441

  9. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Heather Allewelt, Sheel Patel, Aileen Cohen, Constantine S. Tam - Journal of Clinical Oncology 2023 cited by 103

  10. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group

    Authors: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 cited by 197

  11. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nicola Fracchiolla, Austin Kulasekararaj, Toni Valković, Christian Bjørn Poulsen, Marina Machado, Andreas Glenthøj, И. О. Стома, Zdeněk Ráčil, Klára Piukovics, Milan Navrátil, Ziad Emarah, Uluhan Sili, Johan Maertens, Ola Blennow, Rui Bergantim, Carolina García‐Vidal, Lucia Prezioso, Anna Guidetti, Maria Ilaria Del Principe, Marina Popova, Nick de Jonge, Irati Ormazabal‐Vélez, Noemí Fernández, Iker Falces‐Romero, Annarosa Cuccaro, Stef Meers, Caterina Buquicchio, Darko Antić, Murtadha Al‐Khabori, Ramón García‐Sánz, Monika Biernat, Maria Chiara Tisi, Ertan Sal, Laman Rahimli, Nataša Čolović, Martin Schönlein, María Calbacho, Carlo Tascini, Carolina Miranda, Nina Khanna, Gustavo‐Adolfo Méndez, Verena Petzer, Jan Novák, Caroline Besson, Rémy Duléry, Sylvain Lamure, Márcio Nucci, Giovanni Paolo Maria Zambrotta, Павел Зак, Güldane Cengiz Seval, Valentina Bonuomo, Jiřı́ Mayer, Alberto López‐García, Maria Vittoria Sacchi, Stephen Booth, Fabio Ciceri, Margherita Oberti, Marco Salvini, Macarena Izuzquiza, Raquel Nunes Rodrigues, Emanuele Ammatuna, Aleš Obr, Raoul Herbrecht, Lucía Núñez-Martín-Buitrago, Valentina Mancini, Hawraa Shwaylia, Mariarita Sciumé, Jenna Essame, Marietta Nygaard, Josip Batinić and 96 more - Journal of Hematology & Oncology 2021 cited by 318

  12. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Patricia J.T.A. Groenen, Michael Hummel, Elizabeth Macintyre, Κώστας Σταματόπουλος, Christiane Pott, Jan Trka, Nikos Darzentas, Anton W. Langerak - Leukemia 2019 cited by 261

  13. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2021 cited by 85

  14. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia

    Authors: , , , , , , , , , , , , , , , , - Blood Advances 2022 cited by 59

  15. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile

    Authors: , , , , , , , , , , , , , , , , , , - Blood 2013 cited by 173

  16. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2020 cited by 115

  17. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

    Authors: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 350

  18. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , José M. Moraleda, Luis Palomera, Joan Bargay, José A. Martinez‐Climent, Alberto Órfão, Laura Rosiñol, María‐Victoria Mateos, Juan José Lahuerta, Joan Bladé, Jesús F. San Miguel, Bruno Paiva - Blood 2020 cited by 133

  19. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2018 cited by 124

  20. Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , - Cancers 2023 cited by 73

  21. COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2021 cited by 79

  22. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 62

  23. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , C Anderson Kenneth, Michael Attal, Hervé Avet‐Loiseau, Ashraf Badros, Dalsu Baris, Bart Barlogie, Régis Bataille, Meral Beksaç, Andrew Belch, Dina Ben‐Yehuda, Bill Bensinger, P. Leif Bergsagel, Jenny Bird, Joan Bladé, Mario Boccadoro, Michèle Cavo, Asher Chanan‐Khan, Wen Ming Chen, Tony Child, James Chim, Wee Joo Chng, Ray Comenzo, John Crowley, William S. Dalton, Faith E. Davies, Cármino Antônio De Souza, Michel Delforge, Meletios Α. Dimopoulos, Angela Dispenzieri, Johannes Drach, Matthew T. Drake, Brian G.M. Durie, Hermann Einsele, Theirry Facon, Dorotea Fantl, Jean‐Paul Fermand, Rafaël Fonseca, Gösta Gahrton, Ramón García‐Sánz, Christina Gasparetto, Morie A. Gertz, John Gibson, Sergio Giralt, Hartmut Goldschmidt, Philip R. Greipp, Roman Hájek, Izhar Hardan, Parameswaran Hari, Jean‐Luc Harousseau, Hiroyuki Hata, Yutaka Hattori, Tom Heffner, Joy Ho, Vânia Hungria, Shinsuke Ida, Peter Jacob, Sundar Jagannath, Hans Erik Johnsen, Jian Hou, Douglas Joshua, Artur Jurczyszyn, Michio Kawano, Nicolaus Kröger, Shaji Kumar, Robert A. Kyle, Martha Q. Lacy, Juan José Lahuerta, Ola Landgren, Jacob P. Laubach, Jae Hoon Lee and 60 more - Leukemia 2011 cited by 721

  24. Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anna Guidetti, Mariarita Sciumé, Emanuele Ammatuna, Raúl Córdoba, Nicole García‐Poutón, Stefanie K. Gräfe, Alba Cabirta, Dominik Wolf‎, Anna Nordlander, Ramón García‐Sánz, Mario Delia, Caroline Berg Venemyr, Clara Brones, Roberta Di Blasi, Elizabeth de Kort, Stef Meers, Sylvain Lamure, Laura Rubio i Serrano, Maria Merelli, Nicola Coppola, Rui Bergantim, Caroline Besson, Milena Kohn, Jessica Petiti, Carolina García‐Vidal, Michelina Dargenio, François Danion, Marina Machado, Rebeca Bailén, Martin Hoenigl, Giulia Dragonetti, Louis Yi Ann Chai, Chi Shan Kho, Matteo Bonanni, Raphaël Liévin, Francesco Marchesi, Oliver A. Cornely, Livio Pagano - American Journal of Hematology 2022 cited by 72